Status:
TERMINATED
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
Lead Sponsor:
Indiana University School of Medicine
Conditions:
Pancreas Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to find out whether the drug celecoxib has beneficial effects on people with pre-cancerous lesions of the pancreas.
Detailed Description
Efforts at finding a successful chemotherapy for pancreatic cancer have been disappointing. Some patients are at increased risk of pancreatic cancer or may have pre-malignant pancreatic lesions which ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of IPMN
- ECOG Performance status of 0, 1, or 2
- Adequate liver function, bilirubin \< 1.5 times ULN, ALT or AST \< 2.5 times ULN
- Adequate renal function: creatinine \< 1.8
- Must be at least 18
Exclusion
- Use of COX-2 selective inhibitors within the last month
- More than occasional use of NSAIDS in last month (occasional use defined as up to twice weekly dosing)
- CA19-9 levels 1.5 times the ULN
- Active pancreatitis
- Taking sulphonylureas, fluconazole or lithium concomitantly
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00198081
Start Date
September 1 2005
End Date
April 1 2012
Last Update
February 29 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University Hospital
Indianapolis, Indiana, United States, 46202